ÂÜÀòÂÒÂ×

Jeff Behrens is founder and CEO of LabShares Newton, a biotech incubator for biotech startups run by biotech entrepreneurs. Formerly, Jeff was President and CEO of Siamab Therapeutics, a biotech company focused on developing antibodies targeting glycan targets in cancer that exited in 2018. Previously, Jeff served as Senior Director, Business Development and Operations at Edimer Pharmaceuticals (funded by Third Rock Ventures) and also worked at Alnylam and Biogen Idec, where co-founded Biogen’s Innovation Incubator. In 2003 Jeff sold his healthcare IT company, The Telluride Group, to mindSHIFT Technologies, a Fidelity-funded rollup. Jeff has an MS from the Harvard/MIT Division of Health Sciences and Technology (HST), an MBA from MIT Sloan, and graduated from Harvard College. He teaches HST590, a PhD level course at MIT and lives in Newton, MA.